News

Shares of Revolution Medicines (NASDAQ: RVMD) were up more than 20% as of 2 p.m. ET after the company announced positive phase 1/1b trial data for two cancer therapies. The clinical-stage biotech's

Shares of Vertex Energy (NASDAQ: VTNR) zoomed on Friday and were trading 10% higher as of 11 a.m. ET after the company projected better-than-expected throughput volumes for its third quarter. The

Shares of Vertex Energy (NASDAQ: VTNR) zoomed on Friday and were trading 10% higher as of 11 a.m. ET after the company projected better-than-expected throughput volumes for its third quarter. The

Shares of Vertex Energy (NASDAQ: VTNR) zoomed on Friday and were trading 10% higher as of 11 a.m. ET after the company projected better-than-expected throughput volumes for its third quarter. The

On Oct. 1, Viatris (NASDAQ: VTRS) made an announcement that's sure to shake up its fortunes. It's divesting nearly all of its over-the-counter (OTC) medicines, its entire women's healthcare segment

On Oct. 1, Viatris (NASDAQ: VTRS) made an announcement that's sure to shake up its fortunes. It's divesting nearly all of its over-the-counter (OTC) medicines, its entire women's healthcare segment

Large companies often turn to acquisitions to jump-start revenue and earnings growth or to speed up research and development, among other reasons. However, these moves aren't always successful, so

Large companies often turn to acquisitions to jump-start revenue and earnings growth or to speed up research and development, among other reasons. However, these moves aren't always successful, so

Large companies often turn to acquisitions to jump-start revenue and earnings growth or to speed up research and development, among other reasons. However, these moves aren't always successful, so

Bristol Myers Squibb (NYSE: BMY) has historically been a growth machine, always on the hunt for acquisitions and ways to get bigger and better. But acquisitions have also been a bit of a necessity

The U.S. Federal Trade Commission (FTC) allowed Amgen's (NASDAQ: AMGN) purchase of Horizon Therapeutics to go through last month and the company announced the closing of the deal in a press release

The U.S. Federal Trade Commission (FTC) allowed Amgen's (NASDAQ: AMGN) purchase of Horizon Therapeutics to go through last month and the company announced the closing of the deal in a press release

The U.S. Federal Trade Commission (FTC) allowed Amgen's (NASDAQ: AMGN) purchase of Horizon Therapeutics to go through last month and the company announced the closing of the deal in a press release

Over the course of 2007 to 2021, growth stocks dramatically outperformed value stocks. Historically low interest rates, coupled with the emergence of the knowledge economy, sparked one of the

Novavax (NASDAQ: NVAX) fell behind in the original coronavirus vaccine race as rivals Pfizer and Moderna brought their products to market. The biotech launched its vaccine a year-and-a-half later in

Shares of Ardelyx (NASDAQ: ARDX) were down more than 12% as of 3:30 p.m. on Wednesday. The healthcare company, which has a chronic kidney disease (CKD) drug that is awaiting approval later this

Medical device giant Abbott Laboratories (NYSE: ABT) hasn't performed well in the past year. The company has had to deal with several issues that affected its results and its public image, notably

Intellia Therapeutics (NASDAQ: NTLA) has announced a good deal of positive news in recent months, from progress in clinical trials to an expanded partnership with big biotech Regeneron

Gene-editing specialist Intellia Therapeutics (NASDAQ: NTLA) has caught the attention of Cathie Wood. The founder and CEO of Ark Invest, an investment management firm focused on investing in

Shares of Scilex Holdings (NASDAQ: SCLX) were up around 14% as of 2:30 p.m. ET on Monday. The healthcare stock is still down more than 55% this year.

Scilex makes non-opioid pain management products

Shares of Tango Therapeutics (NASDAQ: TNGX) were down more than 12% as of 11:15 a.m. on Monday. The healthcare stock is up more than 37% this year.

Tango is a clinical-stage biotech that focuses on

Gene editing is one of the most revolutionary trends in modern medicine. The potential to swap out a person's genes to eliminate and prevent diseases is here, and investors are keenly looking at

Gene editing is one of the most revolutionary trends in modern medicine. The potential to swap out a person's genes to eliminate and prevent diseases is here, and investors are keenly looking at

Gene editing is one of the most revolutionary trends in modern medicine. The potential to swap out a person's genes to eliminate and prevent diseases is here, and investors are keenly looking at

Smart investors are continually looking for new investment ideas. Sometimes, those ideas are so good that they're hard to pass up.

Three Motley Fool contributors think they've picked some stocks